Ownership stake · Activity not yet classified
Verastem Oncology — $7.5 million equity private placement
Transaction overview
Announced
Exact closing date not established.
On January 13, 2025, Verastem Oncology announced a stock purchase agreement with affiliates of Oberland Capital for 1,416,939 common shares and $7.5 million in gross proceeds. The equity investment was separate from a credit facility of up to $150 million. Closing of the stock purchase was expected that day alongside the note financing; the release did not confirm completion.
Selected source-supported transactions; coverage is incomplete. Announcements do not establish completion or that a deal is still pending. Sponsor activity and operating-business transactions are distinct from adviser acquisitions. Unclassified activity is excluded from adviser-only counts.
Source evidence
- Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 ↗
Official firm website · Published Jan 13, 2025
On January 13, 2025, Verastem Oncology announced a stock purchase agreement with affiliates of Oberland Capital for 1,416,939 common shares and $7.5 million in gross proceeds. The equity investment was separate from a credit facility of up to $150 million. Closing of the stock purchase was expected that day alongside the note financing; the release did not confirm completion.